ScripNearly five years after its first approval for neuromyelitis optica spectrum disorder (NMOSD) in June 2020, the US Food and Drug Administration approved Amgen’s Uplizna (inebilizumab) to treat adults
ScripWhile regulatory uncertainty in the US is mounting, Amgen does not expect significant revenue impact from new tariffs implemented under US President Donald Trump, chief financial officer Peter Griffit
ScripA month after shelving its previous lead drug candidate, izokibep, Acelyrin said on 6 January that it is moving lonigutamab into Phase III in thyroid eye disease with a revised dosing regimen from Pha
ScripAnalysts at PwC expect dealmaking in the life sciences sector to pick up in 2025, but they predict more of the kind of dealmaking that the biopharma industry has favored in recent years, such as bolt-